ABOUT THIS EPISODE
Agentic AI is growing in its applications. Google DeepMind and Edison are leveraging the growing capabilities by developing AI Scientists. These platforms are poised to streamline the scientific process, aiding human scientists with a variety of tasks. Meanwhile, despite positive data in its Phase III DMD therapy trial, Regenxbio’s stock fell for a variety of reasons. 10X Genomics and Harvard University are suing Element Biosciences over patents for a multiomics platform. Finally, Bristol Meyers Squibb is partnering with Hengrui Pharma to develop 13 early-stage programs with the potential to grow their investment to a predicted $15 billion in sales.
Join GEN editors Corinna Singleman, PhD, Alex Philippidis, Fay Lin, PhD, and Uduak Thomas for a discussion of the latest biotech and biopharma news.
Listed below are links to the GEN stories referenced in this episode of Touching Base:
Google DeepMind and Edison Are Building the AI Scientist
By Fay Lin, PhD, GEN Edge, May 19, 2026
StockWatch: Regenxbio Tumbles Despite Positive Pivotal Data for DMD Gene Therapy Candidate
By Alex Philippidis, GEN Edge, May 17, 2026
10x Genomics, Harvard Target Element’s Multiomics Platform in Patent Lawsuit
By Alex Philippidis, GEN Edge, May 12, 2026
BMS, Hengrui Pharma Partner on 13 Programs in Up-to-$15.2B Collaboration
By Alex Philippidis, GEN Edge, May 13, 2026
Hosted by Corinna Singleman, PhD
Hosted by Jonathan D. Grinstein, PhD
The State of Precision Medicine Summit
Join us June 3, 2026
Hosted on Acast. See acast.com/privacy for more information.
